Response of BRCA1-mutated gallbladder cancer to olaparib: A case report

被引：3

作者：

Yuan Xie ^{[1
]}

Yan Jiang ^{[2
]}

Xiao-bo Yang ^{[1
]}

An-qiang Wang ^{[1
]}

Yong-chang Zheng ^{[1
]}

Xue-shuai Wan ^{[1
]}

Xin-ting sang ^{[1
]}

Kai Wang ^{[3
]}

Da-Dong Zhang ^{[2
]}

Jia-Jia Xu ^{[2
]}

Fu-gen Li ^{[2
]}

Hai-tao Zhao ^{[1
]}

机构：

[1] Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

[2] Institute of Precision Medicine, 3D Medicines Inc 3. Center for Precision Medicine, Zhejiang University International Hospital

来源：

World Journal of Gastroenterology | 2016年 / 46期

关键词：

BRCA; Mutation; Olaparib; Poly ADP-ribose polymerase inhibitor; gallbladder cancer;

D O I：

暂无

中图分类号：

R735.8 [胆囊、胆道肿瘤];

学科分类号：

100214 ;

摘要：

gallbladder cancer(gbc), although considered as a relatively rare malignancy, is the most common neoplasm of the biliary tract system. the late diagnosis and abysmal prognosis present challenges to treatment. the overall 5-year survival rate for metastatic gbc patients is extremely low. BRC A1 and BRCA2 are the breast cancer susceptibility genes and their mutation carriers are at a high risk for cancer development, both in men and women. Olaparib, an oral poly ADP-ribose polymerase inhibitor, has been approved by the Food and Drug Administration and the European commission for the treatment of ovarian cancer with any BRCA1/2 mutations. the first case of BRCA1-mutated gbc patient who responded to olaparib treatment is reported here.

引用

页码：10254 / 10259

页数：6

共 50 条

[1] Response of BRCA1- mutated gallbladder cancer to olaparib: A case report
Xie, Yuan
Jiang, Yan
Yang, Xiao-Bo
Wang, An-Qiang
Zheng, Yong-Chang
Wan, Xue-Shuai
Sang, Xin-Ting
Wang, Kai
Zhang, Da-Dong
Xu, Jia-Jia
Li, Fu-Gen
Zhao, Hai-Tao
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (46) : 10254 - 10259
[2] Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
Xiong, Fan
Gong, Jing
Wang, Qi
ONCOTARGETS AND THERAPY, 2020, 13 : 6385 - 6391
[3] Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
Li, Xiaofen
Gao, Limin
Qiu, Meng
Cao, Dan
ONCOTARGETS AND THERAPY, 2021, 14 : 2815 - 2819
[4] Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report
Favier, Laure
Truc, Gille
Boidot, Romain
Bengrine-Lefevre, Leila
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (01) : 73 - 75
[5] Chemosensitivity of BRCA1-Mutated Ovarian Cancer Cells and Established Cytotoxic Agents
van Haaften, Caroline
van Eendenburg, Jaap
Boot, Arnoud
Corver, Willem E.
Haans, Lucien
van Wezel, Tom
Trimbos, J. Baptist
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 (08) : 1571 - 1578
[6] Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib A case report
Li, Mao
Mou, Yu
Hou, Shengzhong
Cao, Dan
Li, Ang
MEDICINE, 2018, 97 (45)
[7] Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Tutt, Andrew N. J.
Garber, Judy E.
Kaufman, Bella
Viale, Giuseppe
Fumagalli, Debora
Rastogi, Priya
Gelber, Richard D.
de Azambuja, Evandro
Fielding, Anitra
Balmana, Judith
Domchek, Susan M.
Gelmon, Karen A.
Hollingsworth, Simon J.
Korde, Larissa A.
Linderholm, Barbro
Bandos, Hanna
Senkus, E.
Suga, Jennifer M.
Shao, Z.
Pippas, Andrew W.
Nowecki, Zbigniew
Huzarski, Tomasz
Ganz, Patricia A.
Lucas, Peter C.
Baker, Nigel
Loibl, Sibylle
McConnell, Robin
Piccart, Martine
Schmutzler, Rita
Steger, Guenther G.
Costantino, Joseph P.
Arahmani, Amal
Wolmark, Norman
McFadden, Eleanor
Karantza, Vassiliki
Lakhani, Sunil R.
Yothers, Greg
Campbell, Christine
Geyer, Charles E.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) : 2394 - 2405
[8] Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas
Hunter, Sally M.
Ryland, Georgina L.
Moss, Phillip
Gorringe, Kylie L.
Campbell, Ian G.
AMERICAN JOURNAL OF PATHOLOGY, 2014, 184 (06) : 1871 - 1876
[9] Combining Carbon-ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
Kawanishi, Miki
Fujita, Mayumi
Karasawa, Kumiko
BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2022, 16
[10] Durable response to Olaparib in EGFR and somatic BRCA2-mutated lung adenocarcinoma with leptomeningeal metastases: a case report
Hou, Fang-fang
Liu, Li-rong
Zhao, Wen-jie
Qu, Yan-chun
Zhou, Rui
Wang, Tian-lin
Ye, Yong-song
Chai, Xiao-shu
Zhang, Hai-bo
FRONTIERS IN ONCOLOGY, 2025, 15

← 1 2 3 4 5 →